- Home
- NXTC vs ERNA Comparison
NXTC vs ERNA Comparison
Compare NXTC & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ERNA
- Stock Information
- Founded
- NXTC 2015
- ERNA 2018
- Country
- NXTC United States
- ERNA United States
- Employees
- NXTC N/A
- ERNA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- ERNA Health Care
- Exchange
- NXTC Nasdaq
- ERNA Nasdaq
- Market Cap
- NXTC 12.8M
- ERNA 13.5M
- IPO Year
- NXTC 2019
- ERNA N/A
- Fundamental
- Price
- NXTC $5.12
- ERNA $1.59
- Analyst Decision
- NXTC Strong Buy
- ERNA
- Analyst Count
- NXTC 2
- ERNA 0
- Target Price
- NXTC $25.50
- ERNA N/A
- AVG Volume (30 Days)
- NXTC 318.4K
- ERNA 85.2K
- Earning Date
- NXTC 08-07-2025
- ERNA 08-13-2025
- Dividend Yield
- NXTC N/A
- ERNA N/A
- EPS Growth
- NXTC N/A
- ERNA N/A
- EPS
- NXTC N/A
- ERNA N/A
- Revenue
- NXTC N/A
- ERNA $488,000.00
- Revenue This Year
- NXTC N/A
- ERNA N/A
- Revenue Next Year
- NXTC N/A
- ERNA N/A
- P/E Ratio
- NXTC N/A
- ERNA N/A
- Revenue Growth
- NXTC N/A
- ERNA 201.24
- 52 Week Low
- NXTC $2.69
- ERNA $1.50
- 52 Week High
- NXTC $19.80
- ERNA $28.80
- Technical
- Relative Strength Index (RSI)
- NXTC 48.99
- ERNA 37.07
- Support Level
- NXTC $4.75
- ERNA $1.62
- Resistance Level
- NXTC $5.23
- ERNA $1.70
- Average True Range (ATR)
- NXTC 0.31
- ERNA 0.10
- MACD
- NXTC 0.02
- ERNA 0.01
- Stochastic Oscillator
- NXTC 53.28
- ERNA 20.73
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.